Schedule

Performance Shipping Inc. Announces Filing of Amendment No. 2 to the Solicitation and Recommendation Statement on Schedule 14D-9

Retrieved on: 
Wednesday, November 15, 2023
Restatement, Security (finance), Indian stock exchange, Committee, Offer and acceptance, AND, Schedule

2 to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the SEC on October 25, 2023, as amended by Amendment No.

Key Points: 
  • 2 to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the SEC on October 25, 2023, as amended by Amendment No.
  • The Company’s Schedule 14D-9 and the Offeror’s Schedule TO may be obtained at no charge at the website maintained by the SEC at www.sec.gov .
  • This press release does not constitute an offer to purchase or solicitation of an offer to sell any Shares or other securities.
  • The Company has filed a solicitation/recommendation statement on Schedule 14D-9, as amended, with the SEC and the Offeror has filed its Offer materials on Schedule TO, as amended, with the SEC.

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, VLP, Disease, COPD, Acquisition, Heart, AstraZeneca, RSV, Food, Virus-like particle, Security (finance), Incidence, Pneumonia, Human, Risk, US Foods, Protein, Mortality, Vaccination, Fast track (FDA), Patient, Urinary tract infection, Letter, Death, Vaccine, Hepatitis, Infection, Immune Therapy Holdings, University, Virus, Communication, SARS-CoV-2, VWAP, Viral pneumonia, Asthma, Immunity (medical), Schedule, Respiratory syncytial virus, Pharmaceutical industry

Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.

Key Points: 
  • Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
  • Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
  • In Icosavax’s Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.
  • The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.

Arco to Provide Supplemental Materials for Extraordinary General Meeting of Shareholders

Retrieved on: 
Thursday, November 16, 2023
Primary, Secondary, Education, Technology, Software, Other Education, Training, Tripura Merger Agreement, EGM, Sub, SP, Proxy, CITES, Proxy statement, Person, Cayman Islands, Plan, Registrar, AND, Schedule, Auction, Security (finance), Mergers and acquisitions, Exhibit

The Company began mailing the notice and proxy statement relating to the EGM (collectively, the “Proxy Statement”) on or about November 10, 2023.

Key Points: 
  • The Company began mailing the notice and proxy statement relating to the EGM (collectively, the “Proxy Statement”) on or about November 10, 2023.
  • 2 at the EGM, was inadvertently omitted from the Proxy Statement as mailed to the Company’s shareholders.
  • The Surviving Company Amended and Restated Memorandum and Articles of Association can be accessed in Arco’s website ( https://investor.arcoplatform.com/financials/others/ ) or by clicking here .
  • 2, or concerning any other matter related to the EGM, should contact the Company’s Investor Relations Department at [email protected] .

Tony Robbins' Lifelong Mission to Feed Neighbors Reaches Milestone as Feeding America® Partnership Provides Historic 1 Billion Meals

Retrieved on: 
Wednesday, November 29, 2023
Meal, SNAP, Challenge, Feeding America, Life, Moon, Food, Private sector, Supplemental Nutrition Assistance Program, Movement, Second Continental Congress, United, Congress, Moonshot, Human, Schedule, Hunger, Non-governmental organization, United Nations, Agriculture, Food delivery

CHICAGO, Nov. 29, 2023 /PRNewswire/ -- Tony Robbins, #1 New York Times bestselling author, entrepreneur, philanthropist, and the world's #1 life and business strategist, together with Feeding America®, America's leading hunger relief organization, today proudly announce achieving their monumental 1 Billion Meals Challenge goal. This milestone, part of a unique 10-year challenge match campaign to fight hunger and food insecurity in the U.S., was reached significantly ahead of the 2025 target.

Key Points: 
  • In 2012, Mr. Robbins became an ambassador for Feeding America , a. nationwide network of 200 food banks and 60,000 food pantries and meal programs.
  • The 100 Million Meals Challenge grew to become a first-of-its-kind, 10-year 1 Billion Meals Challenge campaign.
  • With the 1 Billion meals milestone achieved, Mr. Robbins sets his sights even higher – aiming to end global food insecurity.
  • The 100 Billion Meals initiative provides resources to create sustainable solutions to end world hunger and food insecurity entirely.

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Friday, November 24, 2023
New Age, ADS, Marketing, Tripura Merger Agreement, Companies Act, Filter (signal processing), Harney Westwood & Riegels, Letter, Schedule, Ropes & Gray, Consortium, Proxy, Form 6-K, TSH, Class A share, Committee, The Company, AND, Support, Holding company, Security (finance), Cayman Islands, Limited, Mergers and acquisitions, Parent, Share (finance)

The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.

Key Points: 
  • The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its independent financial and legal advisors.
  • The Rollover Shareholders have agreed to vote all of the Shares beneficially owned by them in favor of the authorization and approval of the Merger Agreement and the Merger pursuant to the Support Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the "Schedule 13E-3").

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Retrieved on: 
Monday, November 20, 2023
Principal, Safety, Johns Hopkins, MIRA, DSM-IV codes, Hope, CSA, Chairperson, Controlled Substances Act, FDA, Depression, National Network, MD, Partnership, TRD, DEA, Doctor of Philosophy, Suicidal ideation, Mental health, Take-home naloxone program, MDSI, Schedule, Pharmaceutical industry, Ketamine, Esketamine

BALTIMORE, Nov. 20, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.

Key Points: 
  • Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
  • This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.
  • Unlike Ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, in initial pre-clinical studies, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.
  • The combination of this exclusive licensing agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation and development."

VNET Announces US$299 Million Strategic Investment from Shandong Hi-Speed Holdings Group Limited

Retrieved on: 
Thursday, November 16, 2023
Motherboard, Investment, Treasury, Consortium, Choice, Exercise, International investment agreement, ADS, VNET, Consortium Agreement of 1954, IDC, The Company, Schedule, Security (finance), PRC

BEIJING, Nov. 16, 2023 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced that Success Flow International Investment Limited ("Success Flow") and Choice Faith Group Holdings Limited ("Choice Faith") have entered into an investment agreement (the "Investment Agreement") with VNET to make an equity investment in an aggregate amount of US$299 million (the "Proposed Investment") in the Company.

Key Points: 
  • BEIJING, Nov. 16, 2023 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced that Success Flow International Investment Limited ("Success Flow") and Choice Faith Group Holdings Limited ("Choice Faith") have entered into an investment agreement (the "Investment Agreement") with VNET to make an equity investment in an aggregate amount of US$299 million (the "Proposed Investment") in the Company.
  • Both Success Flow and Choice Faith are beneficially owned by Shandong Hi-Speed Holdings Group Limited ("SDHG," 00412.HK), the shares of which are listed on the Main Board of The Hong Kong Stock Exchange.
  • The closing of the Proposed Investment is expected to occur around the end of 2023 or January 2024.
  • "Their investment will further strengthen our balance sheet and fuel innovation as we will cooperatively explore new opportunities in renewable energies with them going forward.

Societal CDMO Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
CGMP, Verapamil, Optimism, Human, Three Months, Drug Enforcement Administration, Workforce, Absorption, CDMO, DEA, GAAP, Drug development, Environment, Growth, Webcast, External commercial borrowing, NIH, Schedule, Bangladesh Technical Education Board, Ground substance, Pharmaceutical industry, Fine chemical, Security (finance), Management, Clothing, EBITDA, Teva, Novartis, Society

ET

Key Points: 
  • ET
    SAN DIEGO and GAINESVILLE, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third quarter and nine months ended September 30, 2023.
  • “Given the achievements of the quarter combined with our leaner and highly focused operation, I wish to emphasize the optimism we have for the future of Societal CDMO.
  • Financial Results for the Three Months Ended September 30, 2023
    Revenues for the quarter ended September 30, 2023, were $23.6 million, compared to $21.6 million for the comparable 2022 period.
  • Financial Results for the Nine Months Ended September 30, 2023
    Revenue for the nine months ended September 30, 2023, was $66.9 million, compared to $65.9 million for 2022.

Arco to Hold Extraordinary General Meeting of Shareholders

Retrieved on: 
Tuesday, November 7, 2023
Primary, Secondary, Education, Data Management, Technology, Software, Other Education, EGM, Registrar, Tripura Merger Agreement, Cayman Islands, Cayman, Person, SP, Proxy, Plan, Rua, AND, Sub, Schedule, Brasília, Holding company, Security (finance), Auction, Exhibit, Mergers and acquisitions

Shareholders of record at the close of business in the Cayman Islands on November 7, 2023 will be entitled to attend and vote at the EGM and any adjournment thereof.

Key Points: 
  • Shareholders of record at the close of business in the Cayman Islands on November 7, 2023 will be entitled to attend and vote at the EGM and any adjournment thereof.
  • INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE SCHEDULE 13E-3 AND OTHER MATERIALS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE MERGER AND RELATED MATTERS.
  • The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed Merger.
  • Information regarding the persons who may be considered “participants” in the solicitation of proxies is set forth in the Schedule 13E-3.

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Woman, AD, PD, Food, MCI, DSM-IV codes, European Medicines Agency, Deficit spending, CIV, GABAA, Risk, Schedule, Sale, Essential tremor, MDD, HD, Workforce, DEA, Acquisition, Webcast, EMA, Safety, Therapy, Patient, D, PPD, Plasma, Tremor, ODD, Zuranolone, Education, Incidence, PAM, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMDA, Diagnosis, Grammatical mood, Nursing, Pharmaceutical industry, Dietary supplement, Surveying, Elevator mechanic, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the treatment of PPD.
  • Restructuring Expenses: Restructuring expenses were $33.6 million in the third quarter of 2023 due to the August 2023 corporate reorganization.
  • ET to review its third quarter 2023 financial results and discuss recent corporate updates.